The state commission in charge of Georgia’s medical marijuana program adopted rules Wednesday for the manufacture and sale of low-THC cannabis oil to patients suffering from a variety of diseases.

“We’re all proud to have some rules in place,” Sid Johnson, chairman of the Georgia Access to Medical Cannabis Commission, said following the unanimous vote. “It is a milestone on the way to achieving our goal of providing a quality product to patients.”

The commission was created by a law the General Assembly passed in 2019 to move Georgia from simply legalizing possession of cannabis oil to allowing marijuana to be grown in the state under close supervision and converted into a product that could be sold to patients enrolled in a state registry.

Patients eligible to receive cannabis oil include those suffering from seizure disorders, Parkinson’s disease, terminal cancer, post-traumatic stress disorder and sickle-cell anemia.

The rules will govern various aspects of the program including the facilities that will produce the oil, the dispensaries where the oil will be sold, and the independent laboratories that will test the product.